CytoImmune Therapeutics
Monrovia, US · Founded 2020 · Delaware corporation
Founders & leadership
WR
Will RoselliniNamed on SEC filing
RT
Richard T SantulliNamed on SEC filing
DW
Douglas WilliamsNamed on SEC filing
KH
Kinam HongNamed on SEC filing
AK
Aleksey KrylovNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$36.5M disclosed across 1 round · 2021
▶$36.5MraisedAug 2021 · 4 investors · BiotechnologyRule 506(b)
▶$36.5MraisedAug 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Will RoselliniExecutive Officer
- Richard T SantulliExecutive Officer
- Douglas WilliamsDirector
- Kinam HongDirector
- Aleksey KrylovExecutive Officer
- Offering amount
- $100.3M
- Amount sold
- $36.5M
- Sales commissions
- $880K
- Placement agents
- Lifesci Capital
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has CytoImmune Therapeutics raised?
- CytoImmune Therapeutics has disclosed $36.5M raised across 1 round.
- Where is CytoImmune Therapeutics headquartered?
- CytoImmune Therapeutics is headquartered in Monrovia, US.